%0 Journal Article %T Histology versus cytology: PD-L1 testing in non-small cell lung cancer %A Takigawa, Nagio %A Ochi, Nobuaki %A Yamane, Hiromichi %J Translational Lung Cancer Research %D 2018 %B 2018 %9 %! Histology versus cytology: PD-L1 testing in non-small cell lung cancer %K %X Immune checkpoint inhibitors (ICIs) such as nivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab have been developed to treat malignant tumors, including non-small cell lung cancer (NSCLC). ICIs inhibit programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) signaling between tumor cells expressing PD-L1 and cytotoxic T lymphocytes expressing PD-1. %U https://tlcr.amegroups.org/article/view/23599 %P S225-S227 %@ 2226-4477